Replies to post #241723 on Avid Bioservices Inc (CDMO)

[revenue_monster]

At this point AZN seems to be front runner for a partnership.

[Protector]

geocappy, more importantly they mention their associations with the centers such as Wistar, Moffit etc and they do ACTIVE work with bavituximab (e.g. Scott Antonia's Ex-vivo at the Moffit Cancer Center).

They host conferences for PPHM (e.g. Australia last year) and sit at the round table.

This conference is in a ball room size place of the hotel.
So PPHM expect's an audience and I am sure (if they are smart) that they handed over PERSONAL invitations to the other boots since everyone is there.

It is NOT an official event of the conference but a PPHM initiative.

I agree with cj that one could die to know what the AstraZeneca woman is going to present. I learned that nothing is ever by coincidence and her title missing MUST have a reason. Possibly competition will want to know what is going to be said too.

The KOLs names are no INDEED fully associated with PPHM/Bavituximab and not just PS supporters.

[biopharm]

SITC'15 PPHM's Booth #121...
NOTE: Join us for a Scientific Session - FRI Nov6 2015 7:30-9:00pm
“The PS Signaling Pathway: A Promising
Therapeutic Target Exploited by
Tumors for Immune Evasion”
PGM:
* Raymond Birge (PhD, Rutgers) http://birgelab.org
* Douglas Graham (MD, PhD, Emory) http://choa.org/Childrens-Hospital-Services/Cancer-and-Blood-Disorders/Meet-the-Team/Physicians-and-Researchers/Douglas-Graham
* Dmitry Gabrilovich (MD, PhD, Wistar Inst.) http://www.wistar.org/our-science/scientists/dmitry-gabrilovich-md-phd
* Rolf Brekken (PhD, UTSW/Dallas) http://www.utsouthwestern.edu/labs/brekken
* Maria Karasarides (PhD, AstraZeneca - Sr. Director, ImmunoOncology, Global Medicines Dev.) http://www.linkedin.com/pub/maria-karasarides-ph-d/6/769/136

Maria no longer at AZ and over at Regeneron ...from Sr Director to Exec Director and Regeneron wanting her PS Targeting knowledge Lag-3?


"Who are the players in LAG-3?

Immutep(now Prima Biomed), Umanis and some French associations and Sanofi , Regeneron and on the other hand GlaxoSK, Parexel, Novartis and BMY. "

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=127642067